Compare Cassava Sciences Inc (FLNA) vs JPMorgan Chase & Co (JPM) Price & Performance

Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.

The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.

JPMorgan Chase (JPM) trades at $342.89, up 2.5% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with $181.85B revenue and $57.05B net income for 2025, though recent cash flow trends show operational challenges. Earnings have beaten expectations in two of the last three quarters, with Q3 2026 results pending. Technical indicators suggest continued upward momentum with key resistance at $346.

JPM offers solid value with a P/E of 14.86 and strong institutional support, but faces risks from negative operating cash flows and geopolitical uncertainty. The consensus price target of $372 suggests 8.5% upside potential, supported by the company's leading ROE in the banking sector and stable dividend payments.